イミダフェナシン
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/01/09 12:05:22」(JST)
[Wiki en表示]
Imidafenacin
|
Systematic (IUPAC) name |
4-(2-methyl-1H-imidazol-1-yl)-2,2-diphenylbutanamide |
Clinical data |
Legal status |
|
Routes |
Oral |
Identifiers |
CAS number |
170105-16-5 Y |
ATC code |
None |
PubChem |
CID 6433090 |
ChemSpider |
4938278 N |
UNII |
XJR8Y07LJO Y |
Chemical data |
Formula |
C20H21N3O |
Molecular mass |
319.40 g/mol |
SMILES
- CC1=NC=CN1CCC(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N
|
InChI
-
InChI=1S/C20H21N3O/c1-16-22-13-15-23(16)14-12-20(19(21)24,17-8-4-2-5-9-17)18-10-6-3-7-11-18/h2-11,13,15H,12,14H2,1H3,(H2,21,24) N
Key:SQKXYSGRELMAAU-UHFFFAOYSA-N N
|
N (what is this?) (verify) |
Imidafenacin (INN) is a urinary antispasmodic of the anticholinergic class. It's molecular weight is 319.40 g/mol
References
- Kobayashi F, Yageta Y, Segawa M, Matsuzawa S (2007). "Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland". Arzneimittelforschung 57 (2): 92–100. doi:10.1055/s-0031-1296589. PMID 17396619.
- Miyachi H, Kiyota H, Uchiki H, Segawa M (June 1999). "Synthesis and antimuscarinic activity of a series of 4-(1-Imidazolyl)-2,2-diphenylbutyramides: discovery of potent and subtype-selective antimuscarinic agents". Bioorg. Med. Chem. 7 (6): 1151–61. doi:10.1016/S0968-0896(99)00003-6. PMID 10428387.
Urologicals, including antispasmodics (G04B)
|
|
Acidifiers |
- Ammonium chloride
- Calcium chloride
|
|
Urinary antispasmodics
(primarily antimuscarinics) |
- Darifenacin
- Emepronium
- Fesoterodine
- Flavoxate
- Imidafenacin
- Meladrazine
- Mirabegron
- Oxybutynin
- Propiverine
- Solifenacin
- Terodiline
- Tolterodine
- Trospium chloride
|
|
Other urologicals |
- Urea analogues: Acetohydroxamic acid
- Salicylhydroxamic acid
- Other: Collagen
- Dimethyl sulfoxide
- Magnesium hydroxide
- Pentosan polysulfate
- Phenazopyridine
- Phenyl salicylate
- Succinimide
|
|
Index of the urinary system
|
|
Description |
- Anatomy
- Physiology
- Development
- Cells
|
|
Disease |
- Electrolyte and acid-base
- Congenital
- Neoplasms and cancer
- Other
- Symptoms and signs
- Urine tests
- Blood tests
|
|
Treatment |
- Procedures
- Drugs
- Intravenous fluids
|
|
|
English Journal
- Long-Term Safety and Efficacy of Two Different Antimuscarinics, Imidafenacin and Solifenacin, for Treatment of Overactive Bladder: A Prospective Randomized Controlled Study.
- Yokoyama T, Koide T, Hara R, Fukumoto K, Miyaji Y, Nagai A.SourceDepartment of Urology, Kawasaki Medical School, Kurashiki, Japan.
- Urologia internationalis.Urol Int.2012 Nov 27. [Epub ahead of print]
- Objective: The aim of this study was to assess the efficacy and safety of long-term treatment with two different antimuscarinics, imidafenacin and solifenacin, in patients with overactive bladder (OAB). Patients and Methods: Male or female patients 20 years of age or older who had urgency (more than
- PMID 23207959
- Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.
- Leone Roberti Maggiore U, Salvatore S, Alessandri F, Remorgida V, Origoni M, Candiani M, Venturini PL, Ferrero S.SourceUniversity of Genoa, San Martino Hospital and National Institute for Cancer Research, Department of Obstetrics and Gynaecology , Largo R. Benzi 1, 16132 Genoa , Italy +01139010511525 ; +01139010511525 ; simone.ferrero@unige.it.
- Expert opinion on drug metabolism & toxicology.Expert Opin Drug Metab Toxicol.2012 Nov;8(11):1387-408. doi: 10.1517/17425255.2012.714365. Epub 2012 Aug 8.
- Introduction: Antimuscarinics (AMs) are the mainstay of pharmacological treatment of overactive bladder (OAB), a symptom complex defined by the presence of urinary urgency, usually associated with frequency and nocturia, with or without urgency urinary incontinence. The AMs used to treat OAB differ
- PMID 22871042
Japanese Journal
- 過活動膀胱患者における尿意と脳機能に対するイミダフェナシンの影響 : リアルタイムNIRS-ウロダイナミクス同時測定による検討
- 榊原 隆次,舘野 冬樹,矢野 仁,高橋 修,杉山 恵,尾形 剛,治田 寛之,岸 雅彦,露崎 洋平,内山 智之,山本 達也,鈴木 淳
- 自律神経 = The Autonomic nervous system 49(3), 180-185, 2012-09-15
- NAID 10031047413
- 神経疾患に伴う過活動膀胱(OAB)と認知機能に対するイミダフェナシンの安全性と効果
Related Links
- "Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland". Arzneimittelforschung ...
- イミダフェナシン(Imidafenacin)の検索ならお薬検索QLife(キューライフ)。お医者さんが 処方する処方薬と、薬局で買える市販薬(OTC)、の効果と副作用、写真、添付文書、 保管方法等を掲載。商品名だけでなく一般名や剤形、色などからも検索可能。
Related Pictures
★リンクテーブル★
[★]
- 英
- imidafenacin
- 商
- ステーブラ、ウリトス
特徴
構造
作用機序
薬理作用
動態
適応
- 過活動膀胱における尿意切迫感、頻尿及び切迫性尿失禁
注意
禁忌
- 1)尿閉を有する(抗コリン作用により排尿時の膀胱収縮が抑制→悪化)
- 2)幽門、十二指腸又は腸管が閉塞及び麻痺性イレウス(抗コリン作用により胃腸の平滑筋の収縮及び運動が抑制→悪化)
- 3)消化管運動・緊張が低下(抗コリン作用により胃腸の平滑筋の収縮及び運動が抑制→悪化)
- 4)閉塞隅角緑内障(抗コリン作用により眼圧上昇→悪化)
- 5)重症筋無力症(抗コリン作用→悪化)
- 6)重篤な心疾患(期外収縮等の心電図異常報告→悪化)
- 7)本剤の成分に対し過敏症の既往歴
副作用
添付文書
- http://www.info.pmda.go.jp/go/pack/2590013F1035_1_06/2590013F1035_1_06?view=body